Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Relypsa's patiromer under FDA review; shares jump

This article was originally published in Scrip

Executive Summary

Shares of Relypsa jumped 7.8% on 15 December after the company said the FDA has accepted for review the new drug application (NDA) for patiromer, a high capacity, oral potassium binder, for oral suspension as a treatment for hyperkalemia, a serious condition caused by abnormally elevated levels of potassium in the blood.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC027237

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel